Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 6Triple Negative Breast Neoplasms 3Recurrence 3Prostatic Neoplasms 3Urinary Bladder Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Turcot syndrome 1Thyroid Neoplasms 1Tertiary Lymphoid Structures 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Non-Muscle Invasive Bladder Neoplasms 1Multiple Myeloma 1Mucopolysaccharidosis I 1Mesothelioma, Malignant 1Lymphoma, T-Cell, Peripheral 1Liposarcoma 1Inhibition of Autophagy Synergizes Anti-tumor Effect 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Genetic Diseases, Inborn 1Gastrointestinal Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Cisplatin 76Radiotherapy 44Cetuximab 40pembrolizumab 39Paclitaxel 34Carboplatin 33Docetaxel 30Fluorouracil 25Radiotherapy, Intensity-Modulated 23Nivolumab 18Drug Therapy 14Radiation 12Erlotinib Hydrochloride 9cemiplimab 8Magnetic Resonance Spectroscopy 8Blood Specimen Collection 8130-nm albumin-bound paclitaxel 8durvalumab 7atezolizumab 7Cyclophosphamide 7Afatinib 7Surveys and Questionnaires 6Surgical Procedures, Operative 6Panitumumab 6Leucovorin 6Esophagectomy 6Chemoradiotherapy 6fludarabine 5aldesleukin 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Squamous Cell × Clinical Trials, Phase II as Topic × Clear all
NCT03636685 2018-08-17

Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

ChineseAMS

Phase 1/2 Unknown
60 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡